

Circ_0001982 accelerates the progression of colorectal cancer *via* sponging microRNA-144

Q. DENG¹, C.-J. WANG², R. HAO³, Q.-Y. YANG²

¹Department of Colorectal Surgery, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

²Department of Anorectum, The Third People's Hospital of Hangzhou, Hangzhou, China

³Department of Gastrointestinal Surgery, ShanDong Energy ZaoZhuang Mining Group Central Hospital, Zaozhuang, China

Qun Deng and Changjian Wang contributed equally to this work

Abstract. – OBJECTIVE: The aim of this study was to uncover the expression pattern and biological function of circ_0001982 in the progression of colorectal cancer (CRC).

PATIENTS AND METHODS: Relative expression level of circ_0001982 in 66 paired CRC tissues and adjacent normal tissues was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The association between circ_0001982 level and clinical indexes of CRC patients was assessed. The effect of circ_0001982 on cell behaviors of HT29 and HCT-116 cells was evaluated *in vitro*. Dual-Luciferase reporter gene assay was conducted to verify the binding relation between circ_0001982 and microRNA-144. Finally, rescue experiments were performed to assess the role of the circ_0001982/microRNA-144 axis in mediating the progression of CRC.

RESULTS: Circ_0001982 was significantly up-regulated in CRC tissues when compared with adjacent normal ones. CRC patients with higher expression level of circ_0001982 showed a significantly higher rate of distant metastasis and worse survival. Knockdown of circ_0001982 remarkably attenuated the proliferative, migratory and invasive capacities of HCT-116 cells. However, opposite results were observed after the overexpression of circ_0001982 in HT29 cells. MicroRNA-144 was verified as a target gene of circ_0001982, which could be negatively regulated by circ_0001982. Furthermore, microRNA-144 was capable of reversing the regulatory effect of circ_0001982 on the proliferative, migratory, and invasive capacities of CRC cells.

CONCLUSIONS: Up-regulated circ_0001982 was closely related to distant metastasis and poor prognosis of CRC. In addition, circ_0001982 attenuated the progression of CRC by negatively regulating microRNA-144.

Key Words:

Circ_0001982, MiRNA-144, Colorectal cancer (CRC), Malignant progression.

Introduction

Colorectal cancer (CRC) ranks third and fourth in morbidity and mortality globally, respectively^{1,2}. Surgical procedures accompanied by postoperative chemotherapy or radiotherapy are preferred strategies for CRC^{3,4}. Nevertheless, postoperative recurrence and metastasis often lead to poor prognosis of CRC patients^{5,6}. Current choice of postoperative therapeutic strategies is based on the TNM staging of CRC patients⁶. However, there is still a lack of biological hallmarks for predicting tumor recurrence and metastasis. Therefore, it is significant to develop prognostic hallmarks for early-stage intervention and improvement of overall survival of CRC^{1,7,8}.

As a classical RNA molecule, circRNA forms a covalently closed continuous loop. It was first discovered in viroids in 1976^{9,10}. CircRNA is widely involved in intervening gene expression and regulation. Functionally, circRNA regulates the transcription of target mRNAs by sponging miRNAs. CircRNA can also form protein complexes accompanied by RNAs. A small part of circRNAs is able to synthesize proteins as transcriptional templates^{11,12}. CircRNA has been found widely distributed in cell components, showing time-, tissue- and disease-specificity¹². Due to the lack of 3' and 5' ends structure, circRNA is resistant to exonuclease. Furthermore, stably expressed circRNA in exosomes, cells, or tissues makes it a promising hallmark for tumor diagnosis and prognosis¹³⁻¹⁵.

In this paper, we first analyzed the expression of circ_0001982 in CRC and investigated its function *in vitro*. After predicting and verifying the target gene of circ_0001982, we further explored their interaction in the progression of CRC.

Patients and Methods

Patients and CRC Samples

Paired CRC tissues and adjacent normal tissues were surgically resected from 66 CRC patients. None of the patients received preoperative anti-tumor therapies. Clinical indexes were collected from CRC patients for further analyses. Informed consent was obtained from patients and their families before the investigation. This study was approved by the Ethics Committee of The Second Affiliated Hospital of Zhejiang University School of Medicine.

Cell Lines and Reagents

CRC cell lines (HT29, HCT8, and HCT-116) and colorectal mucosal cell line (FHC) were provided by ATCC (Manassas, VA, USA). All cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Thermo Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Life Technologies, Gaithersburg, MD, USA) and maintained in a 37°C, 5% CO₂ incubator. A culture medium was replaced every 2-3 days. The cell passage was conducted every 90% of confluence.

Cell Transfection

Transfection plasmids were provided by GenePharma (Shanghai, China). Cells were first pre-seeded into 6-well plates. Cell transfection was performed according to the instructions of Lipofectamine 2000 at 70% of confluence. After 48 h, transfected cells were used for following experiments.

Cell Proliferation Assay

Cells were seeded into 6-well plates at a density of 2 × 10⁵ cells per well at established time points. Absorbance (A) at 490 nm of each sample was detected using Cell Counting Kit (CCK-8) assay (Dojindo Laboratories, Kumamoto, Japan). Finally, the viability curve of cells was plotted.

Transwell Invasion Assay

Transfected cells for 48 h were adjusted to a density of 2.0 × 10⁵/mL. Briefly, 200 μL/well cell suspension was applied in the upper side of the transwell chamber (Millipore, Billerica, MA, USA) pre-coated with Matrigel. Meanwhile, 700 μL medium containing 10% FBS was added to the lower side. After 48 h of incubation, invasive cells to the bottom side were fixed with methanol for 15 min and stained with crystal violet for 20

min. Penetrating cells were observed under a microscope and the number of invading cells was counted. 5 fields of view were randomly selected for each sample.

Wound Healing Assay

Cells were seeded into 6-well plates at a density of 5.0 × 10⁵ cells/well. Until 90% of confluence, 1 mL pipette tip was used for creating a artificial wound in the confluent cell monolayer. The percentage of wound closure was calculated at 24 h, respectively.

Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)

The total RNA was extracted from cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and purified by DNase I treatment. Extracted RNA was reversely transcribed into cDNA using PrimeScript RT Reagent (Takara, Otsu, Shiga, Japan). Obtained cDNA was subjected to qRT-PCR using SYBR® Premix Ex Taq™ (Takara, Otsu, Shiga, Japan). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and U6 were used as internal reference for mRNA and miRNA, respectively. Each sample was performed in triplicate. The relative expression level of the gene was calculated by the 2^{-ΔΔCt} method and analyzed by iQ5 2.0. Primers used in this study were as follows: Circ_0001982: forward: 5'-TAGCAGTCCCCAATCCTTG-3', reverse: 5'-CACAAATCCCATCATTC-3'; GAPDH: forward: 5'-CGCTCTCTGCTCCTCCTGTTC-3', reverse: 5'-ATCCGTTGACTCCGACCTTCAC-3'; miRNA-144: forward: 5'-GGAGAAACGCCG CCACGTATCC-3', reverse: 5'-GCTCGATGGG AGCGATGGACC-3'; U6: forward: 5'-CTCGCTTCGGCAGCACA-3', reverse: 5'-AACGCTTCACGAATTTGCGT-3'.

Dual-Luciferase Reporter Gene Assay

Cells were co-transfected with pmirGLO-circ_0001982-WT/pmirGLO-circ_0001982-MUT/pmirGLO and microRNA-144 mimics/NC using Lipofectamine 2000. 24 h later, co-transfected cells were harvested. The luciferase activity was determined in accordance with the Dual-Luciferase reporter assay system (Promega, Madison, WI, USA).

Statistical Analysis

GraphPad Prism 5 V5.01 (Version X; La Jolla, CA, USA) was used for all statistical analyses. Experimental data were expressed as mean ±

standard deviation (SD). Intergroup differences were analyzed by the *t*-test. Kaplan-Meier curve was introduced to assess the prognosis of CRC patients. Spearman regression test was performed to evaluate the relation between the two genes. $p < 0.05$ was considered statistically significant.

Results

Circ_0001982 Was Highly Expressed in CRC Tissues and Cells

A total of 66 paired CRC tissues and adjacent normal tissues were collected. Circ_0001982 was found significantly up-regulated in CRC tissues when compared with normal tissues (Figure 1A, 1B). Identically, circ_0001982 was significantly up-regulated in CRC cell lines compared to the colorectal mucosal cell line (Figure 1C). Results suggested that circ_0001982 might exert a carcinogenic role in the progression of CRC.

Circ_0001982 Expression Was Correlated with Distance Metastasis and Overall Survival of CRC Patients

The correlation between the circ_0001982 expression level and clinical indexes of CRC patients was assessed. As shown in Table 1, circ_0001982 level was positively correlated with distant metastasis, whereas it was negatively correlated with age, gender, tumor stage and lymphatic metastasis of CRC patients. The Kaplan-Meier curve was depicted by analyzing the follow-up data of CRC patients. The results indicated that the prognosis of CRC patients with high expression of circ_0001982 was remarkably worse (Figure 1D).

Knockdown of Circ_0001982 Suppressed the Proliferation, Migration, and Invasion of CRC Cells

We constructed pcDNA-circ_0001982 and anti-circ_0001982 for altering the circ_0001982 expression. Transfection of pcDNA-circ_0001982 significantly up-regulated circ_0001982 lev-




Figure 1. Circ_0001982 was highly expressed in CRC tissues and cell lines. **A**, Relative level of circ_0001982 in CRC tissues and adjacent normal tissues (n=66). **B**, Relative level of circ_0001982 in 16 paired CRC tissues and adjacent normal tissues. **C**, Relative level of circ_0001982 in CRC cell lines (HT29, HCT8 and HCT-116) and colorectal mucosal cell line (FHC). **D**, Kaplan-Meier curves revealed the overall survival of CRC patients with high and low expression of circ_0001982.




Figure 2. Knockdown of circ_0001982 expressed the proliferation, migration and invasion of CRC cells. **A**, Transfection efficacy of pcDNA-circ_0001982 in HT29 cells and anti-circ_0001982 in HCT-116 cells. **B**, CCK-8 assay showed viability of HT29 cells transfected with pcDNA-circ_0001982 and HCT-116 cells transfected with anti-NC/anti-circ_0001982. **C**, Transwell assay showed invasion of HT29 cells transfected with NC/pcDNA-circ_0001982 and HCT-116 cells transfected with anti-NC/anti-circ_0001982 (magnification $\times 200$). **D**, Wound healing assay showed the percentage of wound closure in HT29 cells transfected with NC/pcDNA-circ_0001982 and HCT-116 cells transfected with anti-NC/anti-circ_0001982 (magnification $\times 40$).

in HT29 cells. However, transfection of anti-circ_0001982 significantly down-regulated its level in HCT-116 cells (Figure 2A). A series of functional experiments revealed that the overexpression of circ_0001982 in HT29 cells significantly accelerated cell viability, the number of invasive cells, and the percentage of wound closure (Figure 2B-2D, left). On the contrary, opposite results were observed after the transfection of anti-circ_0001982 in HCT-116 cells (Figure 2B-2D, right).

MicroRNA-144 Was Down-regulated in CRC

MicroRNA-144 was predicted as the potential target of circ_0001982 in CRC through a bioinformatics method (data not shown). Compared with adjacent normal tissues, microRNA-144 was significantly down-regulated in CRC tissues (Figure 3A). Meanwhile, microRNA-144 was lowly expressed in CRC cell lines as well (Figure 3B). 16 CRC tissues were selected and the relation between circ_0001982 and microRNA-144

Table I. Association of circ_0001982 expression with clinicopathologic characteristics of colorectal cancer.

Parameters	No. of cases	Circ_0001982 expression		p-value
		Low (%)	High (%)	
Age (years)				
<60	28	16	12	0.001
≥60	38	17	21	
Gender				
Male	33	18	15	0.001
Female	33	15	18	
T stage				
T1-T2	38	22	16	0.135
T3-T4	28	11	17	
Lymph node metastasis				
No	41	23	18	0.205
Yes	25	10	15	
Distance metastasis				
No	38	23	15	0.001
Yes	28	10	18	

was evaluated. Spearman regression test showed that a negative relation was observed between circ_0001982 expression and microRNA-144 expression in CRC tissues (Figure 3C). By analyzing the follow-up data, CRC patients with low level of microRNA-144 presented significantly worse survival (Figure 3D).

To further explore the interaction between circ_0001982 and microRNA-144, the luciferase reporter gene assay was conducted. Overexpression of microRNA-144 remarkably decreased the luciferase activity of wild-type circ_0001982, suggesting the binding relation between circ_0001982 and microRNA-144 (Figure 3E).

Circ_0001982 Modulated CRC Progression by Negatively Regulating MicroRNA-144 Expression

MicroRNA-144 has been proved to interact with circ_0001982. Next, we speculated whether circ_0001982 sponged microRNA-144 to mediate cellular behaviors of CRC cells. First of all, transfection efficiency of microRNA-144 mimics and inhibitor in HT29 and HCT-116 cells was verified by qRT-PCR (Figure 4A). Transfection of microRNA-144 mimics in HT29 cells overexpressing circ_0001982 markedly increased cell proliferation, the percentage of wound closure, and the number of invasive cells (Figure 4B-4D). Conversely, transfection of microRNA-144 inhibitor in HCT-116 cells with circ_0001982 knockdown yielded the opposite results (Figure 4B-4D).

Discussion

CRC is a common tumor, whose prognosis depends on TNM staging at the first time of diagnosing. Unlike other malignancies, high-risk adenocarcinoma as early-stage CRC are possible to be cured⁴. The postoperative 5-year survival of early-stage CRC is up to 90%^{5,6}. Current reports have found that the etiology and pathogenesis of CRC are extremely complex. Epigenetic changes and gene mutations are the major reasons for the tumorigenesis of CRC. Meanwhile, genetic factors can also result in the occurrence of CRC (i.e., Lynch syndrome)⁷. In recent years, several researches have mainly focused on developing the effective hallmarks for screening and diagnosing CRC.

Abundant circRNAs have been discovered by bioinformatics methods and sequencing technologies⁹⁻¹¹. Meanwhile, vital functions of circRNAs in the occurrence and progression of tumors have been extensively concerned, especially in the digestive system tumors¹⁶. CircRNAs can sponge corresponding miRNAs and block their functions, thereby altering the expressions of downstream miRNAs^{14,15}. In this study, we revealed that circ_0001982 was significantly up-regulated in CRC. Meanwhile, circ_0001982 expression was related to distant metastasis and overall survival of CRC patients. Overexpression of circ_0001982 remarkably promoted the proliferative, migratory, and invasive capacities of CRC cells. Conversely, opposite results were observed after the knock-




Figure 4 Circ_0001982 modulates CRC progression by negatively regulating miR-144 expression. **A**, Relative level of miR-144 in HT29 cells transfected with pcDNA-circ_0001982+NC/pcDNA-circ_0001982+miR-144 mimics and HCT-116 cells transfected with anti-circ_0001982+NC/anti-circ_0001982+miR-144 inhibitor. **B**, CCK-8 assay showed the viability of HT29 cells transfected with pcDNA-circ_0001982+NC/pcDNA-circ_0001982+miR-144 mimics and HCT-116 cells transfected with anti-circ_0001982+NC/anti-circ_0001982+miR-144 inhibitor. **C**, Wound healing assay showed the percentage of wound closure in HT29 cells transfected with pcDNA-circ_0001982+NC/pcDNA-circ_0001982+miR-144 mimics and HCT-116 cells transfected with anti-circ_0001982+NC/anti-circ_0001982+miR-144 inhibitor (magnification $\times 40$). **D**, Transwell assay showed the migration of HT29 cells transfected with pcDNA-circ_0001982+NC/pcDNA-circ_0001982+miR-144 mimics and HCT-116 cells transfected with anti-circ_0001982+NC/anti-circ_0001982+miR-144 inhibitor.

expression of circ_0001982 *in vitro*. The above results suggested that circ_0001982 exerted a carcinogenic role in CRC.

Furthermore, we predicted the miRNA sponged by circ_0001982 through the bioinformatics meth-

od. Finally, microRNA-144 was screened out. QRT-PCR results demonstrated that microRNA-144 was lowly expressed in CRC tissues and cell lines. CRC patients with low expression of microRNA-144 presented a significantly worse survival relative to

those with a high level. These findings verified that circ_0001982 could directly bind to microRNA-144 in CRC cells. Notably, microRNA-144 was capable of reversing the regulatory effect of circ_0001982 on the proliferative, migratory, and invasive abilities of CRC cells. Therefore, circ_0001982 accelerated the malignant progression of CRC *via* negatively regulating microRNA-144.

Conclusions

Collectively, up-regulated circ_0001982 was closely related to distant metastasis and poor prognosis of CRC. Furthermore, circ_0001982 could attenuate the progression of CRC by negatively regulating microRNA-144.

Conflict of Interest

The Authors declare that they have no conflict of interests

References

- 1) YIU AJ, YIU CY. Biomarkers in colorectal cancer. *Anticancer Res* 2016; 36: 1093-1102.
- 2) BRODY H. Colorectal cancer. *Nature* 2015; 521: 321-327.
- 3) WATANABE T, MURO K, AJIOKA Y, HASHIGUCHI Y, NISHIMURA G, SAITO Y, HAMAGUCHI T, ISHIDA H, ISHIMURO M, ISHIOKA S, KANEMITSU Y, KAWANO H, KAWANO T, KOKUDO T, MUROFUSHI K, NAKAJIMA T, OHTSUKA T, SAKAMOTO A, UEHARA K, UENO H, YAMAZAKI T, YOSHIDA T, YOSHINO T, BOKU N, FUJIMORI T, ITABANA T, KOINUMI T, MORITA T, NISHIMURA G, SAKATA Y, SHIMAZONO T, TANAKA S, TSURUTA O, YAMAMOTO T, YAMAMOTO N, TANAKA T, KOTAKE K, SUGIHARA K. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the treatment of colorectal cancer. *Int J Clin Oncol* 2018; 23: 10-30.
- 4) ZHOU Y, JIANG J, GUAN Y, LI H, LIANG JW, PEI W, WANG L, LIU Z, JIANG Z, LIU Y, ZHOU ZX, JIN WS, WANG XS. The short-term effect analysis of intraoperative intraperitoneal perfusion chemotherapy with Irinotecan and Oxaliplatin for colorectal cancer. *J BUON* 2017; 22: 442-448.
- 5) MAHAR AL, COMPTON C, HALABI S, HESS KR, WEISER MR, GROOME PA. Personalizing prognosis in colorectal cancer: a systematic review of the quality and nature of clinical prognostic tools for survival outcomes. *J Surg Oncol* 2017; 116: 969-978.
- 6) ZHOU L, WANG JZ, WANG JT, WU YJ, GUO H, WANG WB, CAO F, CHENG GX. Correlation analysis of MR/CT on colorectal cancer lymph node metastasis characteristics and prognosis. *Eur J Med Pharmacol Sci* 2017; 21: 1219-1225.
- 7) CUYLE PJ, PRENEN H. Current and future biomarkers in the treatment of colorectal cancer. *World J Belg* 2017; 72: 103-110.
- 8) DAS V, KALITA J, PAL S. Diagnostic and prognostic biomarkers in colorectal cancer: a systematic review of recent advances and challenges. *Biomed Pharmacol* 2017; 87: 8-17.
- 9) LEI B, TIAN Z, FAN W, NI B. Circular RNA: a novel biomarker and therapeutic target for human cancers. *Int J Med Sci* 2019; 16: 292-301.
- 10) TANG YY, WANG PL, GAO Y, WANG WT. Circular RNA_0001982 is lower expressed and serves as a potential biomarker of ovarian cancer prognosis. *Eur Rev Med Pharmacol Sci* 2018; 22: 7178-7182.
- 11) XU XY, ZHOU Y, YU C, SHEN B, FENG JF, YU SR. Advances of circular RNAs in carcinoma. *Biomed Pharmacol* 2018; 107: 59-71.
- 12) FU L, LI T, HU Y, GUO J. Circular RNAs in hepatocellular carcinoma: functions and implications. *Cancer Med* 2018 Jun 1. doi: 10.1002/cam4.1574. [Epub ahead of print]
- 13) SUN H, TANG W, RONG D, JIN H, FU K, ZHANG W, LIU Z, CAO H, CAO X. Hsa_circ_0000520, a potential new circular RNA biomarker, is involved in gastric carcinoma. *Cancer Biomark* 2018; 21: 299-306.
- 14) LEI B, TIAN Z, FAN W, NI B. Circular RNA: a novel biomarker and therapeutic target for human cancers. *Int J Med Sci* 2019; 16: 292-301.
- 15) TANG YY, ZHAO P, ZOU TN, DUAN JJ, ZHI R, YANG SY, YANG DC, WANG XL. Circular RNA hsa_circ_0001982 promotes breast cancer cell carcinogenesis through decreasing miR-143. *DNA Cell Biol* 2017; 36: 901-908.
- 16) FANG Y, MA M, WANG J, LIU X, WANG Y. Circular RNAs play an important role in late-stage gastric cancer: circular RNA expression profiles and bioinformatics analyses. *Tumour Biol* 2017; 39: 1010428317705850.